451 related articles for article (PubMed ID: 25974190)
1. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
[TBL] [Abstract][Full Text] [Related]
2. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
[TBL] [Abstract][Full Text] [Related]
4. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.
Gaudio A; Privitera F; Pulvirenti I; Canzonieri E; Rapisarda R; Fiore CE
Diab Vasc Dis Res; 2014 Jan; 11(1):48-52. PubMed ID: 24227537
[TBL] [Abstract][Full Text] [Related]
5. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin and Dickkopf-1 in renal osteodystrophy.
Cejka D; Herberth J; Branscum AJ; Fardo DW; Monier-Faugere MC; Diarra D; Haas M; Malluche HH
Clin J Am Soc Nephrol; 2011 Apr; 6(4):877-82. PubMed ID: 21164019
[TBL] [Abstract][Full Text] [Related]
7. Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects.
Stavrinou E; Sarafidis PA; Koumaras C; Loutradis C; Giamalis P; Tziomalos K; Karagiannis A; Papagianni A
Kidney Blood Press Res; 2019; 44(4):679-689. PubMed ID: 31382263
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
[TBL] [Abstract][Full Text] [Related]
10. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
11. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.
Fassio A; Idolazzi L; Viapiana O; Benini C; Vantaggiato E; Bertoldo F; Rossini M; Gatti D
Clin Rheumatol; 2017 Oct; 36(10):2377-2381. PubMed ID: 28634697
[TBL] [Abstract][Full Text] [Related]
12. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
Rossini M; Viapiana O; Zanotti R; Tripi G; Perbellini O; Idolazzi L; Bonifacio M; Adami S; Gatti D
Calcif Tissue Int; 2015 May; 96(5):410-6. PubMed ID: 25694360
[TBL] [Abstract][Full Text] [Related]
13. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients.
Lee YT; Ng HY; Chiu TT; Li LC; Pei SN; Kuo WH; Lee CT
Clin Chim Acta; 2016 Jan; 452():38-43. PubMed ID: 26522655
[TBL] [Abstract][Full Text] [Related]
14. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.
Polyzos SA; Anastasilakis AD; Kountouras J; Makras P; Papatheodorou A; Kokkoris P; Sakellariou GT; Terpos E
J Bone Miner Metab; 2016 Jul; 34(4):447-56. PubMed ID: 26056025
[TBL] [Abstract][Full Text] [Related]
15. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
[TBL] [Abstract][Full Text] [Related]
17. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels.
Forster CM; White CA; Turner ME; Norman PA; Ward EC; Hopman WM; Adams MA; Holden RM
Am J Nephrol; 2020; 51(11):871-880. PubMed ID: 33238271
[TBL] [Abstract][Full Text] [Related]
18. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke.
He XW; Wang E; Bao YY; Wang F; Zhu M; Hu XF; Jin XP
Atherosclerosis; 2016 Oct; 253():22-28. PubMed ID: 27573735
[TBL] [Abstract][Full Text] [Related]
19. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of periostin and factors associated with new bone formation in ankylosing spondylitis: Periostin may be associated with the Wnt pathway.
Solmaz D; Uslu S; Kozacı D; Karaca N; Bulbul H; Tarhan EF; Ozmen M; Can G; Akar S
Int J Rheum Dis; 2018 Feb; 21(2):502-509. PubMed ID: 28941122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
